Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982

Online
ISSN
1437-4331
See all formats and pricing
In This Section
Volume 50, Issue 8 (Aug 2012)

Issues

Elevated levels of Nɛ-homocysteinyl-lysine isopeptide in patients on long-term hemodialysis

Marek Kolarz
  • Avitum Poland, Hemodialysis Unit Miechow, Miechow, Poland
/ Rafał Głowacki
  • Department of Environmental Chemistry, University of Lodz, Lodz, Poland
/ Tomasz Stompór
  • Department of Nephrology, Hypertension and Internal Medicine, University of Warmia and Mazury, Olsztyn, Poland
/ Janusz Wyroślak
  • Avitum Poland, Hemodialysis Unit Zgierz, Zgierz, Poland
/ Anetta Undas
  • Corresponding author
  • Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
  • Email:
Published Online: 2012-02-11 | DOI: https://doi.org/10.1515/cclm-2011-0716

Abstract

Background: Nɛ-homocysteinyl-lysine (Nɛ-Hcy-Lys), a product of proteolysis of Nɛ-homocysteinylated proteins, has been discovered recently. We sought to investigate the presence of Nɛ-Hcy-Lys in patients on long-term hemodialysis (HD) and its association with markers involved in atherosclerotic vascular disease.

Methods: We studied 86 patients on long-term (median, 45 months) HD and 95 apparently healthy controls. Nɛ-Hcy-Lys and total homocysteine (tHcy) were assayed using high-performance liquid chromatography. Paraoxonase 1 (PON1), asymmetric dimethylarginine (ADMA), folate, 8-isoprostaglandin F(8-iso-PGF), plasminogen activator inhibitor-1 (PAI-1), C-reactive protein (CRP), together with antibodies against Nɛ-homocysteinylated albumin and hemoglobin, were also measured.

Results: Nɛ-Hcy-Lys was detected in 15 HD patients (17.4%). Those patients had 3.1-times lower PON1 (p<0.0001), 20% higher ADMA (p<0.0001), 30% higher PAI-1 (p<0.0001), 10% lower total cholesterol (p=0.001) and LDL-cholesterol (p<0.0001), together with 20% lower triglycerides (p<0.0001) compared with subjects without measurable Nɛ-Hcy-Lys. Nɛ-Hcy-Lys levels correlated with PON1 (r=–0.62, p<0.0001), ADMA (r=0.58, p<0.0001) and PAI-1 (r=0.59, p<0.0001). Folic acid supplementation, tHcy, folate, autoimmune response to Nɛ-Hcy-proteins, and oxidative stress were not associated with the presence of Nɛ-Hcy-Lys. PON1 is the only independent predictor of the presence of Nɛ-Hcy-Lys in HD patients. None of controls had measurable Nɛ-Hcy-Lys in serum.

Conclusion: The presence of Nɛ-Hcy-Lys in HD patients is relatively infrequent and associated with lipid profile, endothelial dysfunction and impaired fibrinolysis, regardless of tHcy and folate levels.

Keywords: chronic kidney disease; hemodialysis; homocysteine; homocysteine thiolactone; Nɛ-homocysteinyl-lysine; protein homocysteinylation

About the article

Corresponding author: Anetta Undas MD, PhD, Institute of Cardiology, Jagiellonian University Medical College, 80 Pradnicka St. 31-202 Krakow, Poland Phone: +48 12 6143004, Fax: +48 12 4233900


Received: 2011-10-02

Accepted: 2012-01-06

Published Online: 2012-02-11

Published in Print: 2012-08-01



Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2011-0716. Export Citation

Comments (0)

Please log in or register to comment.
Log in